Roche Holding said it would pay Danish biotechnology research company Zealand Pharma up to $5.3 billion under an agreement to ...

No. 4 / 2025Zealand Pharma announces completion of enrollment in the Phase 2b ZUPREME-1 trial of petrelintide in people with ...

Roche & Zealand join forces on petrelintide, advancing obesity treatments with innovative amylin analogs. Find out why this ...

Zealand Pharma (ZLDPF) and Roche (RHHBY) entered a collaboration and license agreement to co-develop and co-commercialize petrelintide as a ...

Basel: Roche has announced that it has entered into an exclusive collaboration and licensing agreement with Zealand Pharma.

Zealand Pharma has named Roche as a development and commercialisation partner for its lead obesity candidate petrelintide, ...

Roche is paying $1.65 billion in confirmed upfront fees to add to its burgeoning obesity pipelin | Roche is paying $1.65 ...

Swiss drugmaker Roche on Wednesday announced a major deal in the weight-loss category, agreeing to pay up to $5.3 billion to ...

Roche has parted with $1.4 billion upfront to secure rights to an obesity candidate developed by Zealand Pharma, taking its ...

Investing.com -- Morgan Stanley (NYSE: MS) upgraded its rating on Zealand Pharma (NASDAQ: ZEAL) shares to Overweight from ...

Initiated in December 2024, the Phase 2b ZUPREME-1 trial is designed to evaluate five target doses of petrelintide up to 9 mg over 42 weeks of treatment. Zealand Pharma remains on track to ...

Initiated in December 2024, the Phase 2b ZUPREME-1 trial is designed to evaluate five target doses of petrelintide up to 9 mg over 42 weeks of treatment. Zealand Pharma remains on track to initiate ...